Literature DB >> 29462222

Cross-Sectional Survey of the Burden of Illness of Rosacea by Erythema Severity.

Julie Harper, James Q Del Rosso, Ilia L Ferrusi.   

Abstract

Rosacea is a chronic skin condition characterized by persistent central facial erythema. To explore the burden of illness of rosacea in US adults, a cross-sectional web-based survey was conducted. Participants answered questions on sociodemographics, clinical characteristics, bothersome symptoms, coping and avoidance behaviors, self-perceptions, and health care resource utilization, and completed 2 quality of life instruments, the 21-item rosacea-specific quality of life questionnaire (RosaQoL) and the 36-item Short Form Health Survey (SF-36). This paper reports the data from the 409 respondents with erythematotelangiectatic rosacea (ETR), analyzed by erythema severity. Mean age was 53.1 years; mild, moderate, or severe erythema was reported by 63.6%, 32.0%, and 4.4% of participants, respectively. Blushing/flushing and bumps/pustules were the most bothersome symptoms across severity subgroups. Participants in all subgroups coped with rosacea by applying make-up and managing their stress and anxiety, and tried to prevent rosacea flares by avoiding sun exposure, specific skin care products, and other triggers. Self-perceptions differed by severity subgroup: satisfaction with facial appearance significantly decreased, and worrying about how people will react and feelings of unattractiveness to others significantly increased, with greater erythema severity (all P less than 0.01). Treatment or assessment of rosacea was sought by 20% of participants in the past 3 months, most commonly from a dermatologist. Metronidazole was the most frequently prescribed topical product across severity subgroups, whereas doxycycline and other oral antibiotics were prescribed most frequently in the severe erythema subgroup. RosaQoL emotional domain scores increased with erythema severity (P equals 0.0035), but none of the SF-36 domain scores differed significantly by erythema severity. These results demonstrate that rosacea is associated with a substantial burden of illness that spans all levels of erythema severity in patients with ETR. Feelings of unattractiveness and the adverse impact of rosacea on emotional quality of life increased with erythema severity. J Drugs Dermatol. 2018;17(2):150-158.

Entities:  

Mesh:

Year:  2018        PMID: 29462222

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

1.  Biophotonic Therapy with Fluorescent Light Energy Decreases Facial Erythema, Improves Signs and Symptoms of Rosacea, and Increases Patient Satisfaction: A Postmarket Study.

Authors:  Martin Wade; Vanessa Charest; Bruno Ballardin; Deirdre Edge; Michael Canova Engelbrecht Nielsen
Journal:  J Clin Aesthet Dermatol       Date:  2021-07-01

2.  Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel.

Authors:  M Schaller; L M C Almeida; A Bewley; B Cribier; J Del Rosso; N C Dlova; R L Gallo; R D Granstein; G Kautz; M J Mannis; G Micali; H H Oon; M Rajagopalan; M Steinhoff; E Tanghetti; D Thiboutot; P Troielli; G Webster; M Zierhut; E J van Zuuren; J Tan
Journal:  Br J Dermatol       Date:  2019-10-16       Impact factor: 9.302

3.  Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study.

Authors:  L F Eichenfield; J Q Del Rosso; J K L Tan; A A Hebert; G F Webster; J Harper; H E Baldwin; L H Kircik; L Stein-Gold; A Kaoukhov; N Alvandi
Journal:  Br J Dermatol       Date:  2019-02-27       Impact factor: 9.302

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.